Thank You

Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.

See you next year in Boston

Coming Soon: Gallery of Photos from the 2014 Trans-Pacific Health Sciences Dialogue

About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.





Who Should Attend


The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • Regeneron: Eylea bests Avastin, Lucentis in DMERegeneron Pharmaceuticals Inc. (NASDAQ:REGN) said top-line data from a comparative effectiveness study using VEGF drugs to treat diabetic macular edema showed its Eylea aflibercept was superior to Avastin bevacizumab and Lucentis ranibizumab from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY).

    In the 660-patient NIH-sponsored study, Regeneron said Eylea led to a greater change in best-corrected visual acuity (BCVA) from baseline to 52 weeks compared to Avastin and Lucentis, the primary endpoint. According to its protocol, the study compared intravitreal injections of 2 mg Eylea, 1.25 mg Avastin and 0.5 mg Lucentis to treat central-involved DME in eyes with visual acuity of 20/32 to 20/320.

    The rates of most adverse events (AEs) were similar for all three drugs, except for overall CV events, which were higher in the Lucentis group than the Eylea and Avastin groups (p<0.01). Rates of arterial thromboembolic events were 2% in the Eylea group, 4% in the Avastin group and 5% the Lucentis group (p-value undisclosed).

    Regeneron declined to provide further comparisons between the trial arms. It said the Diabetic Retinopathy Clinical Research Network (DRCR), which ran the study, will present the detailed data at a future medical conference.

    Eylea is a human fusion protein that binds all forms of VEGF-A and placental growth factor (PGF; PlGF). Avastin is a humanized mAb against VEGF, and Lucentis is a humanized mAb fragment. Only Lucentis and Eylea are approved for DME, although Avastin is used off label at the 1.25 mg dose.

    Regeneron gained $28.93 to $369.64 on Friday, despite news that Amgen Inc. (NASDAQ:AMGN) filed a patent suit against the company over mAbs against proprotein convertase subtilisin/kexin type 9 (PCSK9) (see Top Story).
Read more

Industry News from PharmAsia

  • New Thinking Needed To Invigorate Japan Pharma InnovationIf Japan is to invigorate pharma and biotech innovation there will need to be changes to ways of thinking by both investors and research-based ventures, along with closer co-ordination between academia, industry and the government, suggested participants in a panel discussion at the BioJapan meeting in Yokohama.<img src="" height="1" width="1" />
Read more

Upcoming Supporter Events


Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel
Philadelphia, PA

Read more